Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. - Strober, Bruce; Armstrong, April; Rubant, Simone; Patel, Manish; Wu, Tianshuang; Photowala, Huzefa; Crowley, Jeffrey (Journal of Dermatological Treatment, 2022)